Prenatal screening for fetal aneuploidy can be performed by analyzing cell-free DNA (cfDNA) in maternal blood, which derives from both maternal and placental sources during pregnancy. Placental cfDNA is rapidly cleared from the maternal circulation after delivery, thus cfDNA test results in future pregnancies are not affected by prior pregnancies.No result rates generally fall between 1 and 3 percent. Maternal plasma must contain an adequate amount of fetal cfDNA (fetal fraction) to obtain a rel

Dr Deshpande's pioneering research on cell-free DNA testing in heart transplants, supported by NIH, aims to detect organ rejection non-invasively. The multi-site clinical validation using the PROSPERA assay, has shown strong performance metrics in detecting acute rejection in both adult and pediatric cohorts. Noninvasive dd-cfDNA technology such as ProsperaTM may reduce the need for surveillance biopsies and enhance the standard of post-transplant care. | Research Features